RecruitingPhase 1NCT06435910
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment
10 participants
Start Date
May 11, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- Male and female subjects with multiple myeloma or plasmacytoma
- Very good partial or complete remission (CR) after prior combination therapies.
- Expected survival \> 12 weeks
- Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal
- Voluntary informed consent is given with willingness to continue follow up
Exclusion Criteria4
- Pregnant or lactating women
- Uncontrolled active infection
- HIV or active hepatitis B or hepatitis C infection
- Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
Interventions
BIOLOGICALDC vaccines
Antigen-presenting and immune modifying DCvacs to treat MM
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06435910